Clinical Trial Update: Endothelial Protection in Post COVID-19 Patients With Sulodexide [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Sulodexide for endothelial protection in patients after COVID-19 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endothelial Dysfunction
• Post-acute Sequelae of Sars-cov-2 Infection
• Thrombosis

Drugs mentioned

• Sulodexide (sulodexide)

Snippet

Sponsor: Centro Medico del Noroeste | Conditions: Post COVID-19, Endothelial Dysfunction | Phase 3 | Status: COMPLETED